Recursion Pharmaceuticals Inc.
Clinical trials sponsored by Recursion Pharmaceuticals Inc., explained in plain language.
-
Promising NF2 meningioma drug trial halted early
Disease control TerminatedThis study tested an experimental drug called REC-2282 in people aged 12 and older with progressive meningiomas linked to NF2 gene mutations. The goal was to see if the drug could slow tumor growth or improve survival. The trial was terminated early, so final results are not avai…
Phase: PHASE2, PHASE3 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 17, 2026 04:43 UTC
-
New pill for rare gene-driven cancers shows early promise but trial halted
Disease control TerminatedThis study tested an experimental drug called REC-4881 in 18 adults aged 55+ with advanced solid tumors that have AXIN1 or APC gene mutations. The goal was to see if the drug is safe and shrinks tumors. The trial was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 17, 2026 04:42 UTC
-
Promising c. diff drug trial halted early – only 3 patients enrolled
Disease control TerminatedThis study tested a new medicine called REC-3964 to see if it could stop Clostridioides difficile infections from coming back in adults. The trial was stopped early after only 3 people joined. Researchers were checking safety and whether the drug helped people stay infection-free…
Phase: PHASE2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 12, 2026 13:53 UTC